These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32665418)

  • 1. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
    Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
    Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excretion, Mass Balance, and Metabolism of [
    Katyayan K; Yi P; Monk S; Cassidy K
    Drug Metab Dispos; 2020 Aug; 48(8):698-707. PubMed ID: 32499340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.
    Esaki T; Hirai F; Makiyama A; Seto T; Bando H; Naito Y; Yoh K; Ishihara K; Kakizume T; Natsume K; Myers A; Doi T
    Cancer Sci; 2019 Apr; 110(4):1340-1351. PubMed ID: 30724423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
    Delord JP; Argilés G; Fayette J; Wirth L; Kasper S; Siena S; Mesia R; Berardi R; Cervantes A; Dekervel J; Zhao S; Sun Y; Hao HX; Tiedt R; Vicente S; Myers A; Siu LL
    Invest New Drugs; 2020 Dec; 38(6):1774-1783. PubMed ID: 32410080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, metabolism, and excretion of [
    Ye YE; Woodward CN; Narasimhan NI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.
    Podoll T; Pearson PG; Evarts J; Ingallinera T; Bibikova E; Sun H; Gohdes M; Cardinal K; Sanghvi M; Slatter JG
    Drug Metab Dispos; 2019 Feb; 47(2):145-154. PubMed ID: 30442651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
    Dowty ME; Qiu R; Dantonio A; Niosi M; Doran A; Balesano A; Wright SW; Walker GS; Sharma R
    Drug Metab Dispos; 2024 Jun; 52(7):690-702. PubMed ID: 38719744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Mass Balance, and Biotransformation of [
    Ni S; Ma S; Yu Y; Yu Z; Zhu Y; Sun X; Li L; Sun C; Wang H; Peng P; Gu Z; Zhang H; Wu F; Miao L; Fan J
    Drugs R D; 2024 Sep; 24(3):465-476. PubMed ID: 39231890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401.
    Zhang JW; Deng HB; Zhang CY; Dai JQ; Li Q; Zheng QG; Wan HX; Yu HP; He F; Xu YC; Zhao S; Zhang JYJ
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):669-680. PubMed ID: 31030415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites.
    Glaenzel U; Huth F; Eggimann F; Hackling M; Leuthold LA; Meissner A; Bebrevska L
    Drug Metab Dispos; 2024 Nov; 52(12):1379-1387. PubMed ID: 39313328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Study To Determine the Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Capivasertib in Healthy Male Participants.
    Miller C; Wild M; Zhang Z; Sommavilla R; Shanahan D; Bailey C; Gränfors M; Bragg RA; Dong J; Sidhu S; Cullberg M
    Drug Metab Dispos; 2024 Aug; 52(9):939-948. PubMed ID: 39029948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
    Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
    J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo metabolism of a selective δ-opioid receptor.
    Guo J; Gu C; Zhou D; Elmore CS; Bui KH; Grimm SW
    Drug Metab Dispos; 2011 Oct; 39(10):1883-94. PubMed ID: 21752944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
    Kumar S; Tan EY; Hartmann G; Biddle Z; Bergman AJ; Dru J; Ho JZ; Jones AN; Staskiewicz SJ; Braun MP; Karanam B; Dean DC; Gendrano IN; Graves MW; Wagner JA; Krishna R
    Drug Metab Dispos; 2010 Mar; 38(3):474-83. PubMed ID: 20016053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite.
    Bourdet DL; Yeola S; Hegde SS; Colson PJ; Barnes CN; Borin MT
    Drug Metab Dispos; 2020 Dec; 48(12):1312-1320. PubMed ID: 32978223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
    Bang YJ; Su WC; Schuler M; Nam DH; Lim WT; Bauer TM; Azaro A; Poon RTP; Hong D; Lin CC; Akimov M; Ghebremariam S; Zhao S; Giovannini M; Ma B
    Cancer Sci; 2020 Feb; 111(2):536-547. PubMed ID: 31778267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.